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The aim of this longitudinal study is to present data from 76 female patients treated with bisphosphonates (BPs) for postmen-
opausal osteoporosis and referred to the Unit of Oral Diagnosis and Day Surgery of the University of Milano for diagnosis and
treatment. All patients received a thorough oral examination. The diagnosis of osteonecrosis of the jaw bone (ONJ) was made
from radiographic and clinical ﬁndings. 9% of individuals had BRONJ at ﬁrst visit. Patients with dental or periodontal abscess
were signiﬁcantlymorelikelyto develop BRONJ (OR:2.9,95% CI0.5–15.9).Patientswith osteoporosisreceiving BPsmaydevelop
BRONJ,especially in thepresence ofan active infectious process in themouth.Cliniciansshouldcarefully followup onindividuals
receiving bisphosphonates therapy to avoid the occurrence of osteonecrotic lesions.
1.Introduction
Postmenopausal osteoporosis is a systemic skeletal condition
that aﬀects many millions of women around the world. The
National Institutes of Health Consensus Conference deﬁned
osteoporosisasadisease ofincreased skeletalfragilityaccom-
panied by microarchitectural deterioration and low bone
mineral density (a T score for bone mineral density below
−2.5)[1].Osteoporosispreventionandtreatmenthaverelied
on hormonal treatments such as estrogens and selective
estrogen-receptor modulators, and on anticatabolic drugs
and bone resorption inhibitors including bisphosphonates.
Bisphosphonates are the most widely used anticatabolic
agents in the pharmacological management of postmen-
opausal osteoporosis [2]. These compounds are potent
suppressor ofosteoclast activity, improve trabecular and cor-
tical architecture, and increase bone mineral density thereby
[3] reducing the risk of fracture in women osteoporosis [4].
Since2003,numerousreportsproposedanassociationbe-
tween bisphosphonate use and osteonecrosis of the jaw bone
as a long-term side eﬀect of this class of agents [5]. Accord-
ing to the American Association of Oral and Maxillofacial
Surgeons’ position paper [6], patients may be considered
to have bisphosphonates-related osteonecrosis of the jaw
(BRONJ) if all of the following three characteristics are
present: (1) current or previous treatment with a bispho-
sphonate, (2) exposed, necrotic bone in the maxillofacial
region that has persisted for more than eight weeks, and (3)
no history of radiation therapy to the jaws.
Although BRONJ is a dose-related side eﬀect and it is
more common in cancer patients [7], a recent paper showed
that the frequency of osteoporosis patients on oral BPs
aﬀectedbyBRONJwashigherthanpreviouslyreported(N =
470, 7.8%) [8]. The purpose of this longitudinal study is to
present data from 76 female patients treated with bisphos-
phonates for postmenopausal osteoporosis and referred to
the Unitof Oral Diagnosis and Day Surgery of the University
of Milano for diagnosis and treatment.
2.Materialsand Methods
Starting in2005,all female osteoporoticpatientstreated with
BPs were referred to the Unit of Oral Diagnosis and Day
Surgery for evaluation and management. Before the visit2 ISRN Rheumatology
and treatment, all patients gave written informed consent.
This study was approved by the Director of the Clinic in
accordance with the Declaration of Helsinki. Each patient
received a thorough oral, dental, and periodontal examina-
tion. Each tooth was probed at four sites (three buccally
and one lingually) using a North Carolina probe to measure
probingpocketdepthand recession. Recessionwasmeasured
using the cementoenamel junction as a reference point.
Clinical attachment level (CAL) was then calculated as
probing depth plus recession. Periodontitis was based on
measures of the presence and extent of CAL in at least 20%
of the sites probed, CAL > 4mm. Relevant clinical data
regarding BPs treatment, comorbidities, oral ﬁndings, dental
treatment plan, and past and present dental therapies, were
assessed. Patients were followed up every three months for
routine clinical examination, oral hygiene instructions and
debridement;restorative care, periodontal and dentoalveolar
procedures were provided when needed according to the
American Association of Oral and Maxillofacial Surgeons
guidelines [9]. Adjustment of any ill-ﬁtting dentures was
performed, when necessary.
2.1. BRONJ Diagnosis and Staging. BRONJ diagnosis was
made from radiographic and clinical ﬁndings. Patients were
classiﬁed as having stage 0, I, II, or III. Brieﬂy, patients with
noclinicalevidenceofnecroticbonewere consideredstage 0.
Individuals were included in the stage I group if they had
asymptomatic exposed bone without any evidence of infec-
tion. Stage II group patients had exposed necrotic bone with
clinical evidence of infection. Finally, patients were included
in the stage III group if they had exposed necrotic bone with
evidenceofinfection, pain,andoneormoreofthefollowing:
pathologic fracture, extraoral ﬁstula, or osteolysis extending
to the inferior border of the mandible or sinus ﬂoor.
2.2. BRONJ Management. The management of BRONJ
aimed to reduce lesion size, soft and hard tissue inﬂamma-
tion and to alleviate pain. Nonsurgical treatment included
wide spectrum antibiotics, antifungal agents, and mouth-
washes with an antimicrobial solution. Surgical treat-
ment included debridement without mucosal elevation and
removal of loose segments of bony sequestra.
2.3. Statistical Analysis. We described the distribution of
participants’ characteristics, including demographics, smok-
ing status, medical history, and the prevalence and clinical
features of BRONJ.
We performed a logistic regression analysis to estimate
odds ratios (ORs) and 95% CI for exposures of interest
suchasdiabetes, hypertension, dentalorperiodontalabscess,
multiple dental decays, periodontitis, dental extraction, and
the presence of ONJ. All analyses had a signiﬁcance level of
0.05.
3.Results
Atotalof76Caucasianwomenwereincludedinthisanalysis.
At the time of enrollment, patients ranged in age from 51 to
Table 1: Patients’ characteristics, osteonecrosis of the jaw and den-
tal treatments.
Total (N = 76)
n (%)
Age category
50–60 14 (18.4)
61–70 27 (35.5)
71–79 28 (36.9)
80+ 7 (9.2)
Median (IQR) 69 (62–74)
Smokingstatus
Never 56 (73.7)
Current 9 (11.8)
Former 11 (14.5)
Medical history
Hypertension
No 50 (65.8)
Yes 26 (34.2)
Cardiovascular disease
No 60 (78.9)
Yes 16 (21.1)
Immunosuppressant
No 72 (94.7)
Yes 4 (5.3)
Previous radio/chemotherapy
No 73 (96.1)
Yes 3 (3.9)
BPs and BRONJ
BPs treatment
Alendronate 47 (61.8)
Clodronate 16 (21.1)
Ibandronate 3 (3.9)
Risedronate 10 (13.2)
ONJ at ﬁrst visit
No 69 (90.8)
Yes 7 (9.2)
ONJ Stage
0 57 (89.1)
I3 ( 4 . 7 )
II 4 (6.3)
ONJ Site
Maxilla 1 (14.3)
Jaw Bone 6 (85.7)
Oral care
Minor ONJ surgery
No 72 (94.7)
Yes 4 (5.3)
Dental treatment
No 31 (40.8)
Yes 45 (59.2)
ONJ: Osteonecrosis of the jaw; BPs: Bisphosphonates.
91 years, with a median age of 69 years (interquartile range
62–74)(Table1).Approximately12%ofthewomenreported
current smoking.ISRN Rheumatology 3
Table 2: Univariate analysis of associationswith osteonecrosis of the jaw bone.
ONJ
Total (N = 76) No (N = 69) Yes (N = 7) Odds ratio (95% CI) P value
n (%) n (%) n (%)
Diabetes
No 72 (94.7) 66 (91.7) 6 (8.3) 1.0 .26
Yes 4 (5.3) 3 (75.0) 1 (25.0) 3.7 (0.3–40.9)
Hypertension
No 50 (65.8) 44 (88.0) 6 (12.0) 1.0 .24
Yes 26 (34.2) 25 (96.2) 1 (3.8) 0.3 (0.1–2.6)
Suppuration
No 70 (92.1) 69 (98.6) 1 (1.4) 1.0 <.01
Yes 6 (7.9) 0 (0.0) 6 (100.0) ∞ (<0.001–∞)
Multiple dental decays
No 29 (38.2) 24 (82.8) 5 (17.2) 1.0 .06
Yes 47 (61.8) 45 (95.7) 2 (4.3) 0.2 (0.1–1.2)
Periodontitis
No 17 (22.4) 17 (100.0) 0 (0.0) 1.0 .05
Yes 59 (77.6) 52 (88.1) 7 (11.9) ∞ (<0.001–∞)
Dental extraction
No 39 (51.3) 37 (94.9) 2 (5.1) 1.0 .20
Yes 37 (48.7) 32 (86.5) 5 (13.5) 2.9 (0.5–15.9)
ONJ: Osteonecrosis of the jaw.
In addition, 34.2% suﬀered from hypertension, 21.1%
had cardiovascular disease, 5.3% of patients reported having
diabetes, 5.3% were in treatment with an immunosuppres-
sant agent, and 3.9% previously underwent chemo- and
radiotherapy. Multiple dental decays and periodontitis were
present in 61.8% and 77.6% of the individuals, respectively.
All patients were aﬀected by osteoporosis and were treat-
ed with bisphosphonates.
61.8% of patients were receiving Alendronate, 21.1%
Clodronate, 3.9% Ibandronate, or 13.2% Risedronate. Pa-
tients had received BPs consecutively for a mean duration of
time of 191 weeks (95% CI, 150.9–230.7).
3.1. BRONJ Patients. Of these 76 patients, seven (9.2%) had
active ONJ at ﬁrst visit and were being treated in our clinics
(Table 1). Three patients were classiﬁed as being stage I, and
four individuals were stage II. Among these, the majority
(85.7%) was in the mandible while 14.3% had ONJ in the
maxilla. The triggering events for ONJ were identiﬁed as
previous dentoalveolar surgery (n = 2), local trauma from
dentures (n = 3), and periodontal infection (n = 2).
All BRONJ patients received wide spectrum antibiotic
therapy, and four patients underwent surgical debridement.
No alternative treatments were chosen.
3.2. Treatment Outcome. Closure of the exposure and com-
plete remission was obtained in 4 cases out of 7.
At present none of the non-ONJ patients submitted to
invasive dental treatments developed ONJ signs and/or
symptoms.
3.3. BRONJ-Associated Factors. Individuals with dental or
periodontal abscess were signiﬁcantly more likely to develop
ONJ (Table 2). A borderline association was present among
individuals with periodontitis (P = .05). Women with a
positive history for diabetes had a signiﬁcant increase in the
oddsofhavingONJ(OR:3.7,95%CI0.3–40.9).Patientswho
underwent dental extraction while receiving BPs therapy
were three times more likely to develop ONJ (OR: 2.9, 95%
CI 0.5–15.9).
No signiﬁcant associations were observed for the follow-
ing variables: age, smoking status, type of BPs used, hyper-
tension, cardiovascular disease, immunosuppressant, previ-
ous radio- and chemotherapy, and multiple dental decays.
4.Discussion
Bisphosphonates are the most widely prescribed drugs for
the treatment of osteoporosis, with more than 190 million
prescriptions dispensed worldwide [10]. The results of our
analysis showed that the incidence of ONJ attributable to
the use of bisphosphonates was 9%. Our ﬁndings are in
agreement with those of Otto et al. [8], who conducted a
large multicenter trial on the relationship between ONJ and
the use ofBPs and showed that 7.8%of cases(N = 470)were
associated with oral BPs therapy due to osteoporosis.
Patients with diabetes were four times more likely to
developONJ. The risk increased also for patients who under-
went dental-alveolar procedures and for those women who
had periodontal disease and dental or periodontal abscess.
Our results are also consistent with those from a paper by the
M. D. Anderson Cancer Center group [11], which reported4 ISRN Rheumatology
that patients who had a dental or periodontal abscess and
were taking bisphosphonates, were at a seven-fold increased
risk for developing BRONJ.
Individuals who had dental extractions were three times
more likely to be diagnosed with BRONJ. Data presented
by Hoﬀ et al. [12] showed that cancer patients with a
positive history of dental extractions were associated with a
signiﬁcant increase in the odds of detecting ONJ (OR: 13.2;
95% CI 3.7–47.3; P<. 0001). However, our odds ratios are
lower than those reported by Hoﬀ and colleagues. It may be
suggested that cancer patients have a slower healing process
than cancer-free but osteoporotic patients; both radiation
therapy and chemotherapy can aﬀect the ability of cells to
reproduce, which slows the healing process in the mouth
[13]. In addition, chemotherapy may reduce the number of
white blood cells and weaken the immune system, making it
easierforthepatienttodevelopaninfection.Assuch,therisk
of ONJ is signiﬁcantly increased.
Though small numbers limited our ability to fully evalu-
atetherisk factors forONJ,noassociations wereobservedfor
tobaccouse, presence of multipledecays, previousradiother-
apy and/or chemotherapy, or concomitant use of immuno-
suppressant medications. Another limitation to note for this
study isthat ourstudy populationwas hospital based. There-
fore, our results may not be generalizable to the population
at large. In order to overcome these sample-size issues,
multicentric population-based case-control studies are war-
ranted.
5.Conclusions
Our ﬁndings indicate that patients with osteoporosis receiv-
ing BPs may develop osteonecrosis of the mandible, espe-
c i a l l yi nt h ep r e s e n c eo fa na c t i v ei n f e c t i o u sp r o c e s si nt h e
mouth such as periodontal disease or suppuration. In ad-
dition, management of this condition requires the use of
prolonged medical treatment and may require oral surgical
procedures. As such, there is an urgent need to ﬁll a knowl-
edge gap in better characterizing this condition, identifying
themain cause, and determining individual susceptibilityfor
the intervention and prevention of BRONJ. To follow up
on our ﬁndings, additional large clinical trials that aim to
ﬁnd how to overcome bisphosphonate-associated ONJ and
to predict who may beneﬁt from bisphosphonate treatment
without accompanying risk of ONJ are warranted. In
the meantime, patients receiving bisphosphonates therapy
should be followed carefully to avoid the occurrence of ex-
tended osteonecrotic lesions.
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